Department of Nephrology, Graduate School of Medical Science, Tokushima University, Tokushima, Japan
Health Care Center, Kitasato University, Sagamihara, Kanagawa, Japan.
Diabetes. 2018 May;67(5):986-993. doi: 10.2337/db17-1043. Epub 2018 Feb 28.
Diabetic nephropathy (DN) is the major cause of end-stage kidney disease, but early biomarkers of DN risk are limited. Herein we examine urinary IgG4 and Smad1 as additional early DN biomarkers. We recruited 815 patients with type 2 diabetes; 554 patients fulfilled the criteria of an estimated glomerular filtration rate (eGFR) >60 mL/min and no macroalbuminuria at baseline, with follow-up for 5 years. Patients without macroalbuminuria were also recruited for renal biopsies. Urinary IgG4 and Smad1 were determined by enzyme-linked immunoassays using specific antibodies. The specificity, sensitivity, and reproducibility were confirmed for each assay. Increased urinary IgG4 was significantly associated with lower eGFR. The level of urinary IgG4 also significantly correlated with surface density of peripheral glomerular basement membrane (Sv PGBM/Glom), whereas Smad1 was associated with the degree of mesangial expansion-both classic pathological findings in DN. Baseline eGFR did not differ between any groups; however, increases in both urinary IgG4 and Smad1 levels at baseline significantly predicted later development of eGFR decline in patients without macroalbuminuria. These data suggest that urinary IgG4 and Smad1 at relatively early stages of DN reflect underlying DN lesions and are relevant to later clinical outcomes.
糖尿病肾病(DN)是终末期肾病的主要原因,但 DN 风险的早期生物标志物有限。在此,我们研究了尿 IgG4 和 Smad1 作为额外的早期 DN 生物标志物。我们招募了 815 名 2 型糖尿病患者;554 名患者符合估计肾小球滤过率(eGFR)>60mL/min 且基线时无大量白蛋白尿的标准,并随访 5 年。还招募了无大量白蛋白尿的患者进行肾活检。尿 IgG4 和 Smad1 采用特异性抗体的酶联免疫吸附法测定。每种检测方法的特异性、敏感性和可重复性均得到了确认。尿 IgG4 增加与较低的 eGFR 显著相关。尿 IgG4 的水平也与外周肾小球基底膜的表面密度(Sv PGBM/Glom)显著相关,而 Smad1 与系膜扩张的程度相关-这两者都是 DN 的典型病理发现。任何组之间的基线 eGFR 均无差异;然而,无大量白蛋白尿患者的基线时尿 IgG4 和 Smad1 水平的升高均显著预测了以后 eGFR 的下降。这些数据表明,DN 相对早期阶段的尿 IgG4 和 Smad1 反映了潜在的 DN 病变,与以后的临床结局相关。